Latest news
Cytokinetics' aficamten trial met both primary endpoints; Q4 filing expected - Stock TitanStock Titan · Thu, 06 Aug 2026 20:00:00 GMTNICE Recommends Cytokinetics' MYQORZO for Obstructive Heart Muscle Disease - Stock TitanStock Titan · Thu, 30 Jul 2026 10:20:00 GMTCytokinetics (CYTK) insider schedules 24,000-share option-related stock sale - Stock TitanStock Titan · Thu, 30 Jul 2026 07:00:00 GMT